American Head & Neck Society

Advancing Education, Research, and Quality of Care for the Head and Neck oncology patient.

Published on by Miriam Lango

Miriam Lango – Houston, Texas

Practice Contact Information

MD Anderson Cancer Center
1515 Holcombe Boulevard

Houston
Texas
77030
United States

Phone:
Email:
Web Site:

Areas of surgical specialization in Head and Neck Surgery

Endocrine Surgery, Head and Neck Surgeon

Biography/Statement

I was a faculty member at the Fox Chase Cancer Center for 15 years prior to joining MD Anderson Cancer Center in 2019. As a faculty member at comprehensive cancer centers, I believe that multidisciplinary head and neck and endocrine cancer care will yield the best outcomes for patients. My research endeavors have involved functional outcomes and quality of life in head and neck cancer, and health care delivery issues and tumor markers. These endeavors are more fully described below. My research and clinical experience have laid the groundwork for quality of life studies in other tumor types.

Clinical Trials

Bibliography

 

  1. Ebersole B, Lango M, Ridge J, et al. Dysphagia Screening for Pneumonia Prevention in a Cancer Hospital: Results of a Quality/Safety Initiative. Otolaryngol Head Neck Surg. 2019: Dec 3 ePub.
  2. Roldan CS, Chen JJ, Fareed MM, Hameed MY, Churilla TM, Lango MN et al. Impact of primary tumor-specific growth rate on treatment failure for nonropharyngeal head and neck cancers. 2019 ePub.
  3. Lee CT, Lehrer EJ, Aphale A, Lango M, Galloway TJ, Zaorsky NG. Surgical excision, Mohs micrographic surgery, external-beam radiotherapy, or brachytherapy for indolent skin cancer: An international meta-analysis of 58 studies with 21,000 patients. 2019 Oct 15;125(20):3582-3594.
  4. Dong Y, Ridge JA, Ebersole B, Li T, Lango MN et al. Incidence and outcomes of radiation-induced late cranial neuropathy in 10-year survivors of head and neck cancer. Oral oncology. 2019; 95:59-64.
  5. Tang, J and Lango M. Diverging incidence trends for larynx and tonsil cancer in low socioeconomic regions of the US. Oral oncology. 2019 Apr; 91:65-68.
  6. Ebersole B, Soni RS, Moran K, Lango M, Devarajan K, Jamal N. The Role of Occupational Voice Demand and Patient-Rated Impairment in Predicting Voice Therapy Adherence. Journal of voice : official journal of the Voice Foundation 2018; 32:325-331.
  7. Moten AS, Lango MN, Goel N, Goldberg AJ. Regional diagnostic rates, treatments, and outcomes among patients with invasive ductal carcinoma. The Journal of surgical research 2018; 229:114-121.
  8. Zuniga SA, Lango MN. Effect of rural and urban geography on larynx cancer incidence and survival.Laryngoscope. 2018 Aug;128(8):1874-1880.
  9. Dong Y, Ridge JA, Li T, Lango M, et al. Long-term toxicities in 10-year survivors of radiation treatment for head and neck cancer. Oral oncology 2017; 71:122-128.
  10. Ebersole B, Soni RS, Moran K, Lango M et al. The Role of Occupational Voice Demand and Patient-Rated Impairment in Predicting Voice Therapy Adherence. Journal of voice : official journal of the Voice Foundation2018 May;32(3):325-331.
  11. Wang LS, Handorf EA, Ridge JA, Burtness B, Lango M et al. Lymph-node-positive cutaneous nonmelanoma skin cancer: A poor-prognosis disease in need of treatment intensification. Ear, nose, & throat journal 2017; 96:E12-e18.
  12. Liu JC, Sopka DS, Mehra R, Lango M et al. Early oral tongue cancer initially managed with surgery alone: Treatment of recurrence. World J Otorhinolaryngol Head Neck Surg 2016; 2:193-197.
  13. Smith A, Handorf E, Arjmand E, Lango MN. Predictors of regional Medicare expenditures for otolaryngology physician services. 2017;127(6):1312-1317.
  14. Beck TN, Georgopoulos R, Shagisultanova EI, Sarcu D, Handorf EA, Dubyk C, Lango MN et al. EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer. Mol Cancer Ther. 2016 Oct: 15 (10): 2486-2497.
  15. Lango MN, Handorf E, Arjmand E. The geographic distribution of the otolaryngology workforce in the United States. Laryngoscope 2016 Oct 24.
  16. Koshkareva Y, Liu JC, Lango M, Galloway T, Gaughan JP, Ridge JA. Cervical metastases in squamous cell carcinoma of the hard palate and maxillary alveolus. Ear Nose Throat J. 2016 Oct-Nov;95(10-11):E6-E11.
  17. Beck TN, Georgopoulos R, Shagisultanova EI, Sarcu D, Handorf EA, Dubyk C, Lango MN, et al. EGFR and RB1 as dual markers in HPV-negative head and neck cancer. Mol Cancer Ther. 2016 Oct;15(10):2486-2497.
  18. Azadarmaki R, Then MT, Walia R, Lango MN. Cavernous hemangioma of the submandibular gland with parapharyngeal extension in an adult: Case report. Ear Nose Throat J. 2016 Feb;95(2):E11-3.
  19. Lango MN, Galloway T, Mehra R, Ebersole B, Liu J, Moran K, Ridge JA. Impact of baseline patient-reported dysphagia on acute gastrostomy placement in patients with head and neck squamous cell carcinoma undergoing definitive radiation. Head Neck. 2016 Apr;38 Suppl 1:E1318-24.
  20. Beck TN, Kaczmar J, Handorf E, Nikonova A, Dubyk C, Peri S, Lango M, Ridge JA, Serebriiskii IG, Burtness B, Golemis EA, Mehra R. Phospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck. Oncotarget 2015 Aug 7;6(22):18863-74.
  21. Aaron H, Azadarmaki R, Lango MN. Unilateral Vocal Cord Motion Impairment After 1 Dose of Vincristine: Case Report and Literature Review. Am J Ther. 2016 Mar-Apr;23(2):e621-3.
  22. Patel SA, Abdollahi H, Ridge JA, Chang EI, Lango MN, Topham NS. Asymptomatic Deep Peroneal Vein Thrombosis During Free Fibula Flap Harvest: A Review of the Literature, Strategies for Preoperative Assessment, and an Algorithm for Reconstruction. Ann Plast Surg. 2016 Apr;76(4):468-71.
  23. Lango MN, Galloway T, Mehra R, Ebersole B, Liu J, Moran K, Ridge JA. Impact of baseline patient-reported dysphagia on acute gastrostomy placement in patients with head and neck squamous cell carcinoma undergoing definitive radiation. Head Neck. 2016 Apr;38 Suppl 1:E1318-24.
  24. Cracchiolo J, Ridge JA, Egleston B, Lango M. Practice arrangement and Medicare physician payment in otolaryngology. Otolaryngol Head Neck Surg. 2015 Jun;152(6):979-87.
  25. Arrangoiz R, Galloway TJ, Papavasiliou P, Ridge JA, Lango MN. Metastatic cervical carcinoma from an unknown primary: literature review. Ear Nose Throat J. 2014 Apr-May;93(4-5):E1-10. Review.
  26. Lango MN, Egleston B, Fang C, Burtness B, Galloway T, Liu J, Mehra R, Ebersole B, Moran K, Ridge JA. Baseline health perceptions, dysphagia, and survival in patients with head and neck cancer. 2014 Mar 15;120(6):840-7.
  27. Doss M, Kolb HC, Walsh JC, Mocharla V, Fan H, Chaudhary A, Zhu Z, Alpaugh RK, Lango MN, Yu JQ. Biodistribution and radiation dosimetry of 18F-CP-18, a potential apoptosis imaging agent, as determined from PET/CT scans in healthy volunteers. J Nucl Med. 2013 Dec;54(12):2087-92.
  28. Keller LM, Galloway TJ, Holdbrook T, Ruth K, Yang D, Dubyk C, Flieder D, Lango MN, Mehra R, Burtness B, Ridge JA. p16 status, pathologic and clinical characteristics, biomolecular signature, and long-term outcomes in head and neck squamous cell carcinomas of unknown primary. Head Neck. 2014 Dec;36(12):1677-84.
  29. Mehra R, Zhu F, Yang DH, Cai KQ, Weaver J, Singh MK, Nikonova AS, Golemis EA, Flieder DB, Cooper HS, Lango M, Ridge JA, Burtness B. Quantification of excision  repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers. Clin Cancer Res. 2013 Dec 1;19(23):6633-43.
  30. Sopka DM, Li T, Lango MN, Mehra R, Liu JC, Burtness B, Flieder DB, Ridge JA, Galloway TJ. Dysplasia at the margin? Investigating the case for subsequent therapy in ‘low-risk’ squamous cell carcinoma of the oral tongue. Oral Oncol. 2013 Nov;49(11):1083-7.
  31. Fang CY, Egleston BL, Ridge JA, Lango MN, Bovbjerg DH, Studts JL, Burtness BA, Einarson MB, Klein-Szanto AJ. Psychosocial functioning and vascular endothelial growth factor in patients with head and neck cancer. Head Neck. 2014 Aug;36(8):1113-9.
  32. Lango M, Flieder D, Arrangoiz R, Veloski C, Yu JQ, Li T, Burtness B, Mehra R, Galloway T, Ridge JA. Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression. 2013 Sep;23(9):1099-105.
  33. Fang CY, Longacre ML, Manne SL, Ridge JA, Lango MN, Burtness BA. Informational Needs of Head and Neck Cancer Patients. Health Technol (Berl). 2012 Apr 1;2(1):57-62.
  34. Galloway TJ, Lango MN, Burtness B, Mehra R, Ruth K, Ridge JA. Unilateral neck therapy in the human papillomavirus ERA: accepted regional spread patterns. Head 2013 Feb;35(2):160-4.
  35. Andrews G, Lango M, Cohen R, Feigenberg S, Burtness B, Mehra R, Ahmed S, Nicolaou N, Gaughan J, Ridge JA. Nonsurgical management of oropharyngeal, laryngeal, and hypopharyngeal cancer: the Fox Chase Cancer Center experience. Head Neck. 2011 Oct;33(10):1433-40.
  36. Turaka A, Li T, Sharma NK, Li L, Nicolaou N, Mehra R, Burtness B, Cohen RB, Lango MN, Horwitz EM, Ridge JA, Feigenberg SJ. Increased recurrences using intensity-modulated radiation therapy in the postoperative setting. Am J Clin Oncol. 2010 Dec;33(6):599-603.
  37. Turaka A, Li T, Nicolaou N, Lango MN, Burtness B, Horwitz EM, Ridge JA, Feigenberg SJ. Use of a conventional low neck field (LNF) and intensity-modulated radiotherapy (IMRT): no clinical detriment of IMRT to an anterior LNF during the treatment of head-and neck-cancer. Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):65-70.
  38. Rusthoven KE, Feigenberg SJ, Raben D, Kane M, Song JI, Nicolaou N, Mehra R, Burtness B, Ridge J, Swing R, Lango M, Cohen R, Jimeno A, Chen C. Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1020-5.
  39. Lango MN, Egleston B, Ende K, Feigenberg S, D’Ambrosio DJ, Cohen RB, Ahmad S, Nicolaou N, Ridge JA. Impact of neck dissection on long-term feeding tube dependence in patients with head and neck cancer treated with primary radiation or chemoradiation. Head Neck. 2010 Mar;32(3):341-7.
  40. Lango MN, Andrews GA, Ahmad S, Feigenberg S, Tuluc M, Gaughan J, Ridge JA. Postradiotherapy neck dissection for head and neck squamous cell carcinoma: pattern of pathologic residual carcinoma and prognosis. Head Neck. 2009 Mar;31(3):328-37.
  41. Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res. 2006 Sep 1;12(17):5064-73.
  42. Lango M, Wentzel AL, Song JI, Xi S, Johnson DE, Lamph WW, Miller L, Grandis JR. Responsiveness to the retinoic acid receptor-selective retinoid LGD1550 correlates with abrogation of transforming growth factor alpha/epidermal growth factor receptor autocrine signaling in head and neck squamous carcinoma cells. Clin Cancer Res. 2003 Sep 15;9(11):4205-13.
  43. Lango MN, Dyer KF, Lui VW, Gooding WE, Gubish C, Siegfried JM, Grandis JR. Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck. J Natl Cancer Inst. 2002 Mar 6;94(5):375-83.
  44. Song JI, Lango MN, Hwang JD, Drenning SD, Zeng Q, Lamph WW, Grandis JR. Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines. Cancer Res. 2001 Aug 1;61(15):5919-25.
  45. Shah SI, Yip L, Greenberg B, Califano JA, Chow J, Eisenberger CF, Lee DJ, Sewell DA, Reed AL, Lango M, Jen J, Koch WM, Sidransky D. Two distinct regions of loss on chromosome arm 4q in primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2000 Sep;126(9):1073-6.
  46. Endo S, Zeng Q, Burke NA, He Y, Melhem MF, Watkins SF, Lango MN, Drenning SD, Huang L, Rubin Grandis J. TGF-alpha antisense gene therapy inhibits head and neck squamous cell carcinoma growth in vivo. Gene Ther.2000 Nov;7(22):1906-14.
  47. Koch WM, Lango M, Sewell D, Zahurak M, Sidransky D. Head and neck cancer in nonsmokers: a distinct clinical and molecular entity. 1999 Oct;109(10):1544-51.
  48. Donohue TJ, Dworkin LD, Ma J, Lango MN, Catanese VM. Antihypertensive agents that limit ventricular hypertrophy inhibit cardiac expression of insulin-like growth factor-I. J Investig Med. 1997 Dec;45(9):584-91.
  49. Linn JF, Lango M, Halachmi S, Schoenberg MP, Sidransky D. Microsatellite analysis and telomerase activity in archived tissue and urine samples of bladder cancer patients. Int J Cancer. 1997 Dec 19;74(6):625-9.
  50. Lee DJ, Koch WM, Yoo G, Lango M, Reed A, Califano J, Brennan JA, Westra WH, Zahurak M, Sidransky D. Impact of chromosome 14q loss on survival in primary head and neck squamous cell carcinoma. Clin Cancer Res.1997 Apr;3(4):501-5.
  51. Califano JA, Johns MM 3rd, Westra WH, Lango MN, Eisele D, Saji M, Zeiger MA, Udelsman R, Koch WM, Sidransky D. An allelotype of papillary thyroid cancer. Int J Cancer. 1996 Dec 20;69(6):442-4.
  52. Donohue TJ, Dworkin LD, Lango MN, Fliegner K, Lango RP, Benstein JA, Slater WR, Catanese VM. Induction of myocardial insulin-like growth factor-I gene expression in left ventricular hypertrophy. 1994 Feb;89(2):799-809.
  53. Catanese VM, Sciavolino PJ, Lango MN. Discordant, organ-specific regulation of insulin-like growth factor-I messenger ribonucleic acid in insulin-deficient diabetes in rats. 1993 Feb;132(2):496-503.